{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:5462224",
      "entity_text" : "mg",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pfam:PF00788",
      "entity_text" : "RA",
      "entity_type" : "family"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Post hoc analysis of the noninterventional, prospective, 24-month GO-NICE study of RA, PsA, and AS patients who initiated GLM 50 mg subcutaneously once monthly in a real-world setting in Germany.",
  "reading_complete" : "2020-07-28T16:10:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T16:07:59Z",
  "trigger" : "initiated",
  "evidence" : [ "RA, PsA, and AS patients who initiated GLM 50 mg" ],
  "pmc_id" : "7211218",
  "score" : 0
}